Cotadutide as an Innovative Approach to Glycemic Control and Weight Reduction in Patients with Type 2 Diabetes - A Contemporary Review
DOI:
https://doi.org/10.12775/QS.2026.54.70704Keywords
type 2 diabetes, cotadutide, GLP-1 receptor agonist, glycemic control, weight reductionAbstract
Background. Type 2 diabetes is a chronic metabolic disorder associated with impaired insulin secretion and insulin resistance, leading to persistent hyperglycemia and multiple complications. Despite advances in pharmacotherapy, many patients fail to achieve optimal metabolic control, highlighting the need for novel therapeutic approaches.
Aim. The aim of this study was to present the current state of knowledge regarding cotadutide as a potential therapeutic option in the treatment of type 2 diabetes, with particular emphasis on its mechanism of action, clinical efficacy, and safety profile.
Materials and methods. A narrative review of available literature was conducted, including clinical trials, meta-analyses, and preclinical studies evaluating the efficacy and safety of cotadutide in patients with type 2 diabetes and related metabolic disorders.
Results. Cotadutide is a dual GLP-1 and glucagon agonist, that demonstrates a significant improvement regarding glycemia, body weight reduction and positive influence on metabolic parameters, in comparison to placebo. Clinical trials showed decrease in HbA1c, body weight and albuminuria, as well as potential benefits in liver and kidney function. The most common adverse effects involve the gastrointestinal tract.
Conclusions. Cotadutide is a promising factor in diabetes type 2 treatment. It shows a broad spectrum of positive effects on metabolic parameters. However, further analysis and large-scale, long-term studies are required to establish its efficacy and safety.
References
DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al.
Type 2 diabetes mellitus. Nature Reviews Disease Primers. 2015;1:15019.
https://doi.org/10.1038/nrdp.2015.19
Ferrannini E, Natali A.
Pathophysiology of insulin resistance in type 2 diabetes. European Heart Journal Supplements. 2018;20(Suppl E):E1–E8.
https://doi.org/10.1093/eurheartj/suy033
Davies MJ, Aroda VR, Collins BS, et al.
Management of hyperglycaemia in type 2 diabetes, 2022. Diabetologia. 2022;65:1925–1966.
https://doi.org/10.1007/s00125-022-05787-2
World Health Organization.
Global report on diabetes. Geneva: WHO; 2016.
https://doi.org/10.1016/S0140-6736(16)31679-8
Ambery PD, Parker VER, Stumvoll M, Posch MG, Heise T, Plum-Mörschel L, et al.
MEDI0382 (cotadutide) in type 2 diabetes. The Lancet. 2018;391(10140):2607–2618.
https://doi.org/10.1016/S0140-6736(18)30726-8
Selvarajah V, Robertson D, Hansen L, et al.
A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney Int. 2024;106(6):1170-1180.
https://doi.org/10.1016/j.kint.2024.08.023
Holst JJ.
The physiology of GLP-1. Physiological Reviews. 2007;87(4):1409–1439.
https://doi.org/10.1152/physrev.00034.2006
Bankir L, Bouby N, Blondeau B, Crambert G.
Glucagon and kidney function. American Journal of Physiology. 2016;311(2):F469–F486.
https://doi.org/10.1152/ajprenal.00560.2015
Parker VER, Hoang T, Schlichthaar H, et al.
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2022;24(7):1360-1369.
https://doi.org/10.1111/dom.14712
Nahra R, Wang T, Gadde KM, et al.
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care. 2021;44(6):1433-1442.
https://doi.org/10.2337/dc20-2151
Ali, M. M., Hafez, A., Abdelgalil, M. S., Hasan, M. T., El‑Ghannan, M. M., Ghogar, O. M., Elrashedy, A. A., & Abd‑ElGawad, M. (2022).
Impact of cotadutide drug on patients with type 2 diabetes mellitus: A systematic review and meta‑analysis. BMC Endocrine Disorders, 22, 113.
https://doi.org/10.1186/s12902-022-01031-5
Asano M, Sekikawa A, Kim H, Gasser RA Jr, Robertson D, Petrone M, Jermutus L, Ambery P.
harmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes. Diabetes Obes Metab. 2021 Aug;23(8):1859-1867.
https://doi.org/10.1111/dom.14412
Shankar SS, Daniels SJ, Robertson D, Sarv J, Sánchez J, Carter D, Jermutus L, Challis B, Sanyal AJ.
Cotadutide in MASH. Clinical Gastroenterology and Hepatology. 2024.
https://doi.org/10.1016/j.cgh.2024.04.017
Klein G, Petrone M, Yang Y, et al.
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis. Clin Gastroenterol Hepatol. 2024 Sep;22(9):1847-1857.e11. doi: 10.1016/j.cgh.2024.04.017.
https://doi.org/10.1007/s40262-023-01239-1
Kamrul-Hasan ABM, Dutta D, Nagendra L, Basavarajappa SD, Girijashankar HB, Joshi A, Pappachan JM.
Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis. World J Diabetes. 2025 Dec 15;16(12):112830.
https://doi.org/10.4239/wjd.v16.i12.112830
Yan, K., Yu, H., & Blaise, B. (2025).
Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis. Acta diabetologica, 62(9), 1359–1370.
https://doi.org/10.1007/s00592-025-02534-y
Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C. Z., Wan, J. Y., & Yuan, C. S. (2024).
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (Clinical research ed.), 384, e076410.
https://doi.org/10.1136/bmj-2023-076410
Abulehia, A., Ayesh, H., Ayesh, O., Jaber, D., Asad, T., Itbaisha, A., Abugharbieh, H., Gharbia, R., Abu-Hilal, L. H., & Leon, B. G. C. (2026).
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. Endocrinology, diabetes & metabolism, 9(2), e70187.
https://doi.org/10.1002/edm2.70187
Habegger K, Heppner K, Geary N, et al.
The metabolic actions of glucagon revisited. Nat Rev Endocrinol 6, 689–697 (2010).
https://doi.org/10.1038/nrendo.2010.187
Boland ML, Laker RC, Mather K, et al.
Cotadutide in NASH. Nature Metabolism. 2020;2(5):413–431.
https://doi.org/10.1038/s42255-020-0209-6
Boland, M. L., Laker, R. C., Mather, K., Nawrocki, A., Oldham, S., Boland, B. B., Lewis, H., Conway, J., Naylor, J., Guionaud, S., Feigh, M., Veidal, S. S., Lantier, L., McGuinness, O. P., Grimsby, J., Rondinone, C. M., Jermutus, L., Larsen, M. R., Trevaskis, J. L., & Rhodes, C. J. (2020).
Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nature metabolism, 2(5), 413–431.
https://doi.org/10.1038/s42255-023-00938-0
Marso SP, Bain SC, Consoli A, et al.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.
https://doi.org/10.1056/NEJMoa1607141
Gerstein HC, Colhoun HM, Dagenais GR, et al.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Zuzanna Wątek, Jan Szewczyk, Alicja Smolińska, Patrycja Krawczyk, Katarzyna Łysynkiewicz, Izabela Grzyb
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 28
Number of citations: 0
